Clinical trials: Hepatocellular Carcinoma Resectable
Hepatocellular Carcinoma (HCC), Hepatocellular Carcinoma Non-Resectable
Observational Study for SIR-Spheres Therapy for the Treatment of HCC Patients in China
Yttrium-90 (y90) Microsphere Injection Solution was approved by the NMPA in 2022. Currently, there is a lack of summary of real-world data in China.
- Trial name
- NCT06712017
- Testing
- Yttrium-90 (Y-90) resin microspheres
- Where
- 6 sites in China
- Volunteers
- 100 people
- Sponsor
- GrandPharma (China) Co., Ltd.
Carcinoma, Hepatocellular
A Study of PTX-9908 Injection for Non-resectable HCC With TACE
This is a multicenter, Phase I/II study in patients with non-resectable hepatocellular carcinoma following TACE treatment. Phase I (Open-label dose escalation) This study will be an open-label study with an Accelerated Phase and…
- Trial name
- NCT03812874
- Testing
- PTX-9908 Injection
- Where
- Taiwan
- Sponsor
- TCM Biotech International Corp.
Hepatocellular Carcinoma Resectable
Drug Sensitivity Testing-Based Tumor Organoids to Guide Adjuvant Therapy After Hepatectomy for Primary Liver Cancer
This is a single-center, prospective, non-randomized, open-label, phase II clinical trial aiming to evaluate the efficacy and feasibility of using patient-derived tumor organoid drug sensitivity testing (ODST) to guide…
- Trial name
- NCT07363356
- Testing
- Organoid Drug Sensitivity Testing-Guided Therapy
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Resectable Hepatocellular Carcinoma With High Risk of Recurrence
The Real-world Study of AK104 Combining With TACE for Resectable Hepatocellular Carcinoma (MORNING)
This is an observational study. All patients who meet the inclusion criteria of our previous Phase 2, open-label, single-arm study of neoadjuvant immune-checkpoint blockade therapy (AK104) combining with TACE for resectable…
- Trial name
- MORNING-RWS (NCT07064681)
- Testing
- Surgery with and without the aid of Indocyanine Green (ICG)
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Sun Yat-sen University
Colorectal Cancer Metastatic
Living Donor Liver Transplant for Unresectable Colorectal Liver Metastases
The goal of this study is to create a data registry to capture clinical, pathologic, and molecular data/outcomes for patients with metastatic colorectal cancer who undergo live donor liver transplantation.
- Trial name
- NCT05248581
- Testing
- Liver transplantation
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Rochester
Hepatocellular Carcinoma, Resectable Hepatocellular Carcinoma
SBRT + Atezolizumab + Bevacizumab in Resectable HCC
This study is evaluating the safety and tolerability of neoadjuvant stereotactic body radiation therapy (SBRT) with atezolizumab and bevacizumab for treating resectable hepatocellular carcinoma.
- Trial name
- NCT04857684
- Testing
- Atezolizumab, Bevacizumab, Stereotactic Beam Radiation Therapy (SBRT)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Massachusetts General Hospital
Hepatocellular Carcinoma Non-resectable
BioPearl™ Microspheres Loaded With Doxorubicin for the Treatment of Unresectable Hepatocellular Carcinoma (HCC)
The primary objective of the study is to confirm safety and technical success of BioPearl™ microspheres loaded with Doxorubicin in the treatment of unresectable hepatocellular carcinoma (HCC).
- Trial name
- BIOPEARL-ONE (NCT05911633)
- Testing
- BioPearl™
- Where
- 10 sites in Belgium, France and 2 more
- Volunteers
- 50 people
- Sponsor
- Terumo Europe N.V.
Primary Liver Cancer, Non-Resectable Hepatocellular Carcinoma
MRI-guided Holmium-166 Radioembolization
To investigate the safety and feasibility of a personalized Ho-166-PLLA-MS TARE approach by using MRI guidance in inoperable patients with HCC.
- Trial name
- EMERITUS-2 (NCT05609448)
- Testing
- MRI-guided radioembolization
- Where
- Netherlands
- Volunteers
- 15 people
- Sponsor
- Radboud University Medical Center
Hepatocellular Carcinoma, Hepatocellular Cancer
Atezolizumab Plus Bevacizumab Alone or Combined with External Beam Radiotherapy for HCC with Macrovascular Invasion
The recent global IMbrave150 study evaluated the combination of atezolizumab and bevacizumab versus sorafenib in 501 patients with advanced or metastatic Hepatocellular Carcinoma (HCC).
- Conditions
- Hepatocellular Carcinoma, Hepatocellular Cancer, Hepatocellular Carcinoma Non-resectable, Hepatocellular Carcinoma Stage IV
- Trial name
- ALERT-HCC (NCT05992220)
- Testing
- Atezolizumab plus bevacizumab, combined EBRT to vascular invasion, Atezolizumab plus bevacizumab
- Where
- South Korea
- Volunteers
- 138 people
- Sponsor
- Asan Medical Center
Hepatocellular Carcinoma
Donafenib Combine With Sintilimab and HAIC in Neoadjuvant of Resectable Hepatocellular Carcinoma
The investigators design a phase IIB clinical study to explore the efficacy and safety of Donafenib combined with Sintilimab and HAIC in neoadjuvant of resectable Hepatocellular Carcinoma.
- Trial name
- NCT06512467
- Testing
- Donafenib, Sintilimab, HAIC
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Hepatocellular Carcinoma Non-Resectable
A Study to Evaluate SHR-1210 in Subjects With Advanced HCC
This a randomized controlled Phase 2/3 study to evaluate the efficacy and safety of SHR-1210 in subjects with advanced HCC who failed or intolerable to prior systemic treatment.
- Trial name
- NCT02989922
- Testing
- SHR-1210
- Where
- 17 sites in China
- Volunteers
- 220 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.